Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Liver transplantation candidates with age ≥ 18 years, no clinical or radiological evidence of active tuberculosis and negative pregnancy test (if applicable)who must meet one or more of the following criteria:~* PPD skin test (initial or after a booster effect) \>5 mm. Alternatively, the determination may be made by the interferon gamma (IFN-g) production in PPD-stimulated lymphocytes using the Quantiferon-TB or ELISPOT assays.~* Past history of tuberculosis not properly treated.~* Past history of contact with a patient with active TB.~* Chest x-ray consistent with past untreated TB (apical fibronodular lesions, calcified solitary nodule, calcified lymph nodes or pleural thickening).~The patient must give their written informed consent.~Exclusion Criteria:~* Lack of consent to participate in the study.~* Intolerance or allergy to levofloxacin or to isoniazid.~* Documented contact with tuberculosis resistant to levofloxacin or to isoniazid.~* Treatment in the previous month with drugs with potential activity against Mycobacterium tuberculosis, (especially quinolones).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- levofloxacin (Type: EXPERIMENTAL): Levofloxacin 500 mg daily for 9 months starting on the waiting list for liver transplant
- Isoniazid (Type: ACTIVE_COMPARATOR): Isoniazid 300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).